On September 12, 2021 Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will participate in the following virtual investor events (Press release, Insmed, SEP 1, 2021, View Source [SID1234587137]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference on September 8, 2021 at 9:45 a.m. ET in a fireside chat
The Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 3:30 p.m. ET in a fireside chat
The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 a.m. ET in a fireside chat available for on-demand viewing
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event on September 22, 2021 in 1×1 investor meetings
The Cantor Fitzgerald Virtual Global Healthcare Conference on September 27, 2021 at 8:00 a.m. ET in a fireside chat
Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the respective presentation dates.

On September 1, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following schedule of investor conferences (Press release, Akebia, SEP 1, 2021, View Source [SID1234587134]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 19th Annual Global Healthcare Conference
Virtual fireside chat at 2:45 p.m. ET on September 9

H.C. Wainwright 23rd Annual Global Investment Conference
On-demand presentation available at 7:00 a.m. ET on September 13

Cantor Fitzgerald Virtual Global Healthcare Conference 2021
Virtual presentation at 2:00 p.m. ET on September 27
Where applicable, live webcasts of Akebia’s fireside chats and presentations will be made available on the Investors section of the Company’s website at View Source .

On September 1, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will participate in two upcoming conferences (Press release, Precigen, SEP 1, 2021, https://www.prnewswire.com/news-releases/precigen-to-present-at-the-2021-wells-fargo-virtual-healthcare-conference-and-the-hc-wainwright-23rd-annual-global-investment-conference-301366548.html [SID1234587133]). Dr. Sabzevari will participate in a virtual fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021 at 8:40 AM ET, and present at the H.C. Wainwright 23rd Annual Global Investment Conference. The H.C. Wainwright webcast will be available on-demand beginning Monday, September 13, 2021 at 7:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may access the webcasts for these events through Precigen’s website in the Press & Events section at investors.precigen.com/events-presentations.

On September 1, 2021 iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, reported that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually on September 13-15, 2021 (Press release, iSpecimen, SEP 1, 2021, https://www.prnewswire.com/news-releases/ispecimen-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-on-september-13-15-2021-301366649.html [SID1234587132]). Dr. Ianelli’s corporate presentation will be available on-demand starting Monday, September 13, 2021 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the H.C. Wainwright conference, or to schedule a one-on-one meeting with iSpecimen’s management, please contact your H.C. Wainwright representative directly or KCSA Strategic Communications at [email protected].

On September 1, 2021 Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported its participation in the following medical and investor conferences (Press release, Aeglea BioTherapeutics, SEP 1, 2021, View Source [SID1234587130]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Meetings

2021 Wells Fargo Virtual Healthcare Conference, September 9
H.C. Wainwright 23rd Annual Global Investment Conference, September 13
2021 Cantor Virtual Global Healthcare Conference, September 27
Medical Conferences

International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021), September 17 – 22
50th Child Neurology Society (CNS) Annual Meeting, September 29 – October 2
At both the MDS Virtual Congress and the CNS Annual Meeting, a poster presentation will outline a subset analysis from the Company’s previously reported Phase 1/2 and Phase 2 open label extension studies of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). In the poster, analysis of gait kinematics and spasticity was completed using video compilations.

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.